3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Squamous Cell Carcinoma of Head and Neck
2
Esophageal Neoplasms
2
Uterine Cervical Neoplasms
1
Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC)
1
Resectable Non-small Cell Lung Cancer
1
Ovarian Neoplasms
1
Nonsquamous Non-small Cell Lung Cancer
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Interventions
Cisplatin
47
Radiotherapy
37
Fluorouracil
23
Cetuximab
17
pembrolizumab
11
Carboplatin
11
Paclitaxel
8
Docetaxel
8
Radiotherapy, Intensity-Modulated
6
Chemotherapy, Adjuvant
6
Surgical Procedures, Operative
5
Standard of Care
5
nimotuzumab
4
Methotrexate
4
Gabapentin
4
Drug Therapy
4
Afatinib
4
Radiotherapy, Conformal
3
Radiation
3
Porfiromycin
3
Nivolumab
3
Neoadjuvant Therapy
3
Fibroblast Growth Factor 7
3
Bleomycin
3
zalutumumab
2
sargramostim
2
epacadostat
2
Tranexamic Acid
2
Tirapazamine
2
Pilocarpine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Head and Neck Neoplasms
×
Platinum Compounds
×
Clear all
NCT04428333
2024-10-09
INDUCE-4
GlaxoSmithKline
Phase 3
Terminated
117 enrolled
33 charts